Poliomyelitis leading to large-scale trials in the then Belgian Congo and the vaccination of seven million children in Poland against serotypes PV1 and PV3 between 1958 and 1960. The second inactivated polio virus vaccine was developed in 1952 by Jonas Salk at the University of Pittsburgh, and announced to the world on 12 April 1955. The Salk vaccine, or inactivated poliovirus vaccine, is based on poliovirus grown in a type of monkey kidney tissue culture (vero cell line), which is chemically inactivated with formalin. After two doses of inactivated poliovirus vaccine (given by injection), 90 percent or more of individuals develop
Salk Hall include the construction of an research tower in the parking area behind the existing building by Ballinger Architects with associates DRS Architects. The new tower is planned to house laboratories and support spaces relocated from their current home in Salk Hall in order to free up space for additional classrooms and offices in the original structure. The target completion date is July, 2014. A dental museum is housed in the first floor reception area of Salk Hall. The museum contains a variety of original dental artifacts, including a c. 1910 dental chair, and x-ray machine and instrument cabinet from the